FDA grants fast track status to Phanes’ spevatamig for advanced BTC

RegulatoryspevatamigPositive

AI Analysis

Summary

Phanes Therapeutics received FDA fast track designation for spevatamig in advanced and metastatic biliary tract cancer, expediting the drug's development and review pathway.

Outcome Details

Fast track designation granted

Importance:5/10

Sentiment:

0.60

fast track designationregulatoryoncologybiliary tract cancer

Read the original article

Published by Pharmaceutical Technology on August 17, 2026 8:42 AM

Read Original